Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids
Sebastian Prill, Andrea Caddeo, Guido Baselli, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 97

Showing 1-25 of 97 citing articles:

FinnGen provides genetic insights from a well-phenotyped isolated population
Mitja Kurki, Juha Karjalainen, Priit Palta, et al.
Nature (2023) Vol. 613, Iss. 7944, pp. 508-518
Open Access | Times Cited: 2257
FinnGen: Unique genetic insights from combining isolated population and national health register data
Mitja Kurki, Juha Karjalainen, Priit Palta, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 350
Update on NAFLD genetics: From new variants to the clinic
Eric Trépo, Luca Valenti
Journal of Hepatology (2020) Vol. 72, Iss. 6, pp. 1196-1209
Open Access | Times Cited: 319
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Josep M. Llovet, Catherine E. Willoughby, Amit G. Singal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 8, pp. 487-503
Closed Access | Times Cited: 195
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Stefano Romeo, Arun J. Sanyal, Luca Valenti
Cell Metabolism (2020) Vol. 31, Iss. 1, pp. 35-45
Open Access | Times Cited: 178
CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload
Riina Harjumäki, Chris S. Pridgeon, Magnus Ingelman‐Sundberg
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8221-8221
Open Access | Times Cited: 150
Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis
Björn Carlsson, Daniel Lindén, Gabriella Brolén, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 142
Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease
Oveis Jamialahmadi, Rosellina Margherita Mancina, Ester Ciociola, et al.
Gastroenterology (2021) Vol. 160, Iss. 5, pp. 1634-1646.e7
Open Access | Times Cited: 117
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 133
Genetic and epigenetic factors determining NAFLD risk
Wenke Jonas, Annette Schürmann
Molecular Metabolism (2020) Vol. 50, pp. 101111-101111
Open Access | Times Cited: 122
LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover
Yuki Tanaka, Yuta Shimanaka, Andrea Caddeo, et al.
Gut (2020) Vol. 70, Iss. 1, pp. 180-193
Open Access | Times Cited: 114
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease
Fei Luo, Federico Oldoni, Avash Das
Hepatology Communications (2021) Vol. 6, Iss. 3, pp. 448-460
Open Access | Times Cited: 91
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne, Giovanni Targher
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 28-43
Open Access | Times Cited: 79
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications
Maria Jiménez Ramos, Lucia Bandiera, Filippo Menolascina, et al.
iScience (2021) Vol. 25, Iss. 1, pp. 103549-103549
Open Access | Times Cited: 79
TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
Miriam Longo, Marica Meroni, Erika Paolini, et al.
Cellular and Molecular Gastroenterology and Hepatology (2021) Vol. 13, Iss. 3, pp. 759-788
Open Access | Times Cited: 78
Modelling metabolic diseases and drug response using stem cells and organoids
Wenxiang Hu, Mitchell A. Lazar
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 12, pp. 744-759
Open Access | Times Cited: 60
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
Kiarash Riazi, Mark G. Swain, Stephen E. Congly, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4556-4556
Open Access | Times Cited: 46
Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives
Sonia Youhanna, Aurino M. Kemas, Lena C. Preiss, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 141-206
Open Access | Times Cited: 39
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
Yinshuang Chen, Weipeng Wang, Maria P. Morgan, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 32
MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 947-964
Open Access | Times Cited: 28
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease
Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, et al.
Nature Medicine (2024)
Open Access | Times Cited: 17
Genetics of MASLD: The State of Art Update.
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2177-2187.e3
Closed Access | Times Cited: 15
Organoid-guided precision hepatology for metabolic liver disease
Sho Osonoi, Takanori Takebe
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 805-821
Closed Access | Times Cited: 11
Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD)
Narendra S. Choudhary, Ajay Duseja
Translational Gastroenterology and Hepatology (2020) Vol. 6, pp. 2-2
Open Access | Times Cited: 70
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Tracey Hurrell, Vlasia Kastrinou-Lampou, Achilleas Fardellas, et al.
Cells (2020) Vol. 9, Iss. 4, pp. 964-964
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top